Compare iShares MSCI Canada (TSX) (EWC) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares MSCI Canada (TSX) trades at $58.86 (market cap $6.99B), while Vertex Pharmaceuticals Incorporated trades at $510.05 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 18.2× iShares MSCI Canada (TSX)'s market cap, and iShares MSCI Canada (TSX) is more actively traded (1,625,847 versus 1,487,944). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Canada (TSX) for 57 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| EWC | VRTX | |
|---|---|---|
Market Cap | $6.99B | $127.55B |
Volume | 1,625,847 | 1,487,944 |
Sector | Broad Market / Factor | Health |
52-Week High | $62.64 | $557.96 |
52-Week Low | $49.72 | $407.37 |
Typical Hold Time | 57 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC trades at $57.94, down 2.1% today amid a bearish technical signal with moving averages indicating selling pressure. The stock lacks disclosed financial ratios, limiting fundamental clarity. Recent news highlights trade tensions between the U.S. and Canada, with potential impacts on cross-border economic activity and market sentiment.
The outlook is clouded by geopolitical risks from U.S.-Canada trade disputes, which could pressure performance. Investment opportunities hinge on resolution of trade frictions and improved economic data. Key risks include prolonged trade uncertainty and volatility from political developments.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
